ReP USP - Resultado da busca

Artigo de periodico
Conversion chemotherapy with a modified FLOX regimen for Borderline or unresectable liver metastases from colorectal cancer: an alternative for limited-resources settings (2019)
Bonadio, Renata Colombo; Divino, Paulo Henrique Amor; Obando, Jorge Santiago Madero; Lima, Karolina Cayres Alvino; Recchimuzzi, Debora Zachello; Kruger, Jaime Arthur Pirola; Saragiotto, Daniel Fernandes; Capareli, Fernanda C.; Hoff, Paulo Marcelo Gehm
Fonte: Journal of global oncology. Unidade: FM
Assuntos: ENVELHECIMENTO, NEOPLASIAS COLORRETAIS, NEOPLASIAS HEPÁTICAS, MEIA IDADE, METÁSTASE NEOPLÁSICA, ESTUDOS RETROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONADIO, Renata Colombo et al. Conversion chemotherapy with a modified FLOX regimen for Borderline or unresectable liver metastases from colorectal cancer: an alternative for limited-resources settings. Journal of global oncology, v. 5, 2019Tradução . . Disponível em: https://doi.org/10.1200/JGO.19.00180. Acesso em: 06 nov. 2024.
APA
Bonadio, R. C., Divino, P. H. A., Obando, J. S. M., Lima, K. C. A., Recchimuzzi, D. Z., Kruger, J. A. P., et al. (2019). Conversion chemotherapy with a modified FLOX regimen for Borderline or unresectable liver metastases from colorectal cancer: an alternative for limited-resources settings. Journal of global oncology, 5. doi:10.1200/JGO.19.00180
NLM
Bonadio RC, Divino PHA, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PMG. Conversion chemotherapy with a modified FLOX regimen for Borderline or unresectable liver metastases from colorectal cancer: an alternative for limited-resources settings [Internet]. Journal of global oncology. 2019 ; 5[citado 2024 nov. 06 ] Available from: https://doi.org/10.1200/JGO.19.00180
Vancouver
Bonadio RC, Divino PHA, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PMG. Conversion chemotherapy with a modified FLOX regimen for Borderline or unresectable liver metastases from colorectal cancer: an alternative for limited-resources settings [Internet]. Journal of global oncology. 2019 ; 5[citado 2024 nov. 06 ] Available from: https://doi.org/10.1200/JGO.19.00180
Trabalho de evento-resumo periodico
Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community (2015)
Protasio, Bruno Mendonca; Matutino, Adriana Reis Brandao; Lage, Liana Valente; De Santana, Iuri Amorim; Ramos, Ricardo Emanuel De Oliveira; Caires-Lima, Rafael; Caires, Inacelli Queiroz De Souza; Riechelmann, Rachel Pimenta; Saragiotto, Daniel Fernandes; Sabbaga, Jorge; Hoff, Paulo Marcelo
Fonte: Journal of Clinical Oncology. Nome do evento: Gastrointestinal Cancers Symposium. Unidade: FM
Assuntos: QUIMIOTERAPIA (EFEITOS ADVERSOS), NEOPLASIAS COLORRETAIS (TERAPIA), TOXICIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PROTASIO, Bruno Mendonca et al. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b. Acesso em: 06 nov. 2024. , 2015
APA
Protasio, B. M., Matutino, A. R. B., Lage, L. V., De Santana, I. A., Ramos, R. E. D. O., Caires-Lima, R., et al. (2015). Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b
NLM
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 nov. 06 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b
Vancouver
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 nov. 06 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b
Trabalho de evento-resumo periodico
A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx) (2015)
Andrade, Daniel Ciampi de; Teixeira, Manoel Jacobsen; Galhardoni, Ricardo; Ferreira, Karine A. S. L.; Malieno, Paula Braz; Scisci, Nathalia; Riechelmann, Rachel Pimenta; Teixeira, William G. J.; Saragiotto, Daniel Fernandes; Silva, Valquiria Aparecida; Raicher, Irina; Castro, Isac de; Parravano, Daniella; Fukushima, Julia Tizue; Lefaucheur, Jean-Pascal; Bouhassira, Didier; Macarenco, Ricardo Silvestre e Silva; Mello, Evandro Sobroza de; Hoff, Paulo Marcelo
Fonte: Journal of Clinical Oncology. Nome do evento: ASCO Annual Meeting. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS (TERAPIA), QUIMIOTERAPIA, DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO (ETIOLOGIA), ANTINEOPLÁSICOS (CLASSIFICAÇÃO;EFEITOS ADVERSOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANDRADE, Daniel Ciampi de et al. A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3575?sid=69988bce-10fd-4808-a054-d0c1d39d5fff. Acesso em: 06 nov. 2024. , 2015
APA
Andrade, D. C. de, Teixeira, M. J., Galhardoni, R., Ferreira, K. A. S. L., Malieno, P. B., Scisci, N., et al. (2015). A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx). Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3575?sid=69988bce-10fd-4808-a054-d0c1d39d5fff
NLM
Andrade DC de, Teixeira MJ, Galhardoni R, Ferreira KASL, Malieno PB, Scisci N, Riechelmann RP, Teixeira WGJ, Saragiotto DF, Silva VA, Raicher I, Castro I de, Parravano D, Fukushima JT, Lefaucheur J-P, Bouhassira D, Macarenco RS e S, Mello ES de, Hoff PM. A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx) [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 nov. 06 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3575?sid=69988bce-10fd-4808-a054-d0c1d39d5fff
Vancouver
Andrade DC de, Teixeira MJ, Galhardoni R, Ferreira KASL, Malieno PB, Scisci N, Riechelmann RP, Teixeira WGJ, Saragiotto DF, Silva VA, Raicher I, Castro I de, Parravano D, Fukushima JT, Lefaucheur J-P, Bouhassira D, Macarenco RS e S, Mello ES de, Hoff PM. A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx) [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 nov. 06 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3575?sid=69988bce-10fd-4808-a054-d0c1d39d5fff

Unidades USP

ReP

Filtros

Autores

Assuntos